Get the Stockscreener App
133.42
1.79%
-2.43
After Hours:
133.40
-0.02
-0.01%
Glaukos Corp stock is traded at $133.42, with a volume of 871.65K.
It is down -1.79% in the last 24 hours and up +18.31% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$135.85
Open:
$137.1
24h Volume:
871.65K
Relative Volume:
1.15
Market Cap:
$7.84B
Revenue:
$507.44M
Net Income/Loss:
$-187.69M
P/E Ratio:
-40.79
EPS:
-3.271
Net Cash Flow:
$-39.06M
1W Performance:
+11.53%
1M Performance:
+18.31%
6M Performance:
+58.17%
1Y Performance:
+53.60%
1-Day Range:
$131.94
$137.87
1-Week Range:
$113.00
$146.75
52-Week Range:
$73.16
$146.75
Glaukos Corp Stock (GKOS) Company Profile
Name
Glaukos Corp
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
133.42 | 7.98B | 507.44M | -187.69M | -39.06M | -3.271 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corp Stock (GKOS) Latest News
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares - Investing.com
Glaukos (GKOS) CFO exercises options and sells 10,000 shares under plan - Stock Titan
Glaukos president & COO Gilliam sells $2.8m in company stock - Investing.com
GLAUKOS (GKOS) President & COO sells 19,573 shares in open-market trade - Stock Titan
GLAUKOS (GKOS) director Leana Wen sells 1,700 shares, holds 19,739 - Stock Titan
Glaukos Corp Leads Innovation in Chronic Eye Disease Treatment with iDose TR and Epioxa Therapies – 2026 Investor Update - Minichart
[8-K] GLAUKOS Corp Reports Material Event - Stock Titan
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations - Yahoo Finance
UBS Group AG Increases Position in Glaukos Corporation $GKOS - MarketBeat
MSN Money - MSN
Earnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$148 - Sahm
Glaukos (NYSE:GKOS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Glaukos Corp. Earnings Call Signals Growth Momentum - The Globe and Mail
[144] GLAUKOS Corp SEC Filing - Stock Titan
Glaukos Up Over 19%, On Track for Largest Percent Increase Since December 2023 -- Data Talk - Moomoo
Fidelity Brokerage Services LLC (GKOS) files Form 144 to sell 19,573 shares - Stock Titan
Glaukos (GKOS) Q1 Loss Of US$0.34 EPS Reinforces Bearish Profitability Narrative - Sahm
GKOS SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
GKOS Maintains Overweight Rating by JP Morgan -- Price Target Ra - GuruFocus
GKOS Maintained by Citigroup -- Price Target Raised to $140 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock - MarketBeat
Glaukos (GKOS) Jumps As Earnings Beat Fuels Bullish Outlook - StocksToTrade
Glaukos stock reaches 52-week high at $143.81 By Investing.com - Investing.com Canada
GKOS Maintained by Wells Fargo -- Price Target Raised to $138.00 - GuruFocus
Midday Stock Roundup: Alignment Healthcare Shares Fall 12% Following Q1 Earnings - Orange County Business Journal
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook - Zacks Investment Research
Glaukos Stock Surges 18% on Record Q1 Sales Beat and Raised 2026 Outlook as iDose TR Demand Soars - International Business Times Australia
GKOS Maintained by BTIG -- Price Target Raised to $141.00 - GuruFocus
GKOS Maintained by Needham -- Price Target Raised to $136 - GuruFocus
Glaukos (GKOS) Rule 144: Fidelity lists 10,000‑share resale, insider trades - Stock Titan
Glaukos (NYSE:GKOS) Sets New 1-Year High After Earnings Beat - MarketBeat
Wells Fargo & Company Raises Glaukos (NYSE:GKOS) Price Target to $138.00 - MarketBeat
Glaukos stock reaches 52-week high at $143.81 - Investing.com UK
Glaukos Corporation (NYSE:GKOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Needham & Company LLC Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock - MarketBeat
Needham raises Glaukos stock price target to $136 on revenue beat By Investing.com - Investing.com South Africa
Needham raises Glaukos stock price target to $136 on revenue beat - Investing.com
BTIG raises Glaukos stock price target to $141 on strong results - Investing.com
BTIG raises Glaukos stock price target to $141 on strong results By Investing.com - Investing.com South Africa
Glaukos Q1 Earnings Call Highlights - MarketBeat
Glaukos Corp (GKOS) Q1 2026 Earnings Call Highlights: Record Sal - GuruFocus
Glaukos Announces First Quarter 2026 Financial Results - BioSpace
Glaukos 1Q Loss $19.8M >GKOS - Moomoo
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Glaukos Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Glaukos (GKOS) Reports Strong Q1 Revenue Growth - GuruFocus
Glaukos (GKOS) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Glaukos Corp beats Q1 2026 forecasts, stock dips By Investing.com - Investing.com Australia
Glaukos (GKOS) Forecasts FY26 Revenue Between $620M and $635M - GuruFocus
Glaukos Corp Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):